A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01571661
First received: March 15, 2012
Last updated: April 3, 2012
Last verified: April 2012
  Purpose

This is a double blind, randomised, placebo controlled, single dose escalation, first-time-in-human, 5-way crossover study to assess the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of ascending doses of GSK189075A in healthy subjects (Part A). Single doses will be given to 10 healthy subjects. The planned doses are 20mg, 50mg, 150mg, 500mg, and 1000mg. Each subject will receive 4 of the 5 active doses and a placebo separated by a washout of 5-10 days. A second cohort of 6 subjects with type 2 diabetes mellitus will receive 2 active doses and a placebo along with oral glucose in a three-way, randomised, placebo controlled, crossover design to assess glucose lowering following GSK189075A administration (Part B). Blood samples will be taken throughout the study day for pharmacokinetic analysis of prodrug and metabolites. Safety will be assessed by measurement of blood glucose, blood pressure, heart rate, ECGs, laboratory safety screens, and collection of adverse events.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: GSK189075A
Other: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Basic Science
Official Title: A Double Blind, Randomized, Placebo Controlled, Single-dose Escalation, First-time-in-human Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Safety and tolerability change from baseline in laboratory assessments [ Time Frame: Part A: Approximately 58 days and Part B: Approximately 38 days. ] [ Designated as safety issue: No ]
    Hematology, Clinical Chemistry, Urinalysis

  • Safety and tolerability change from baseline in electrocardiaogram (ECG) reading [ Time Frame: Part A: Approximately 58 days and Part B: Approximately 38 days. ] [ Designated as safety issue: No ]
    12-lead ECG and continuous ECG monitoring.

  • Safety and tolerability change from baseline in fluid intake [ Time Frame: FPart A: Approximately 58 days and Part B: Approximately 38 days. ] [ Designated as safety issue: No ]
    urine output, and the number of micturations will be recorded.

  • Safety and tolerability change from baseline in electrolytes [ Time Frame: Part A: Approximately 58 days and Part B: Approximately 38 days. ] [ Designated as safety issue: No ]
    Blood electrolyte concentrations (Na, K, Cl, Ca, Mg and bicarbonate)

  • Safety and Tolerability change from baseline in creatinine clearance [ Time Frame: Part A: Approximately 58 days and Part B: Approximately 38 days. ] [ Designated as safety issue: No ]
    creatinine clearance (24-hours [h])

  • Composite of pharmacokinetic parameters of GSK189075A, GSK189074A, and GSK279782A [ Time Frame: Part A: up to 24 hours post dose for five periods. Part B: For 24 hours post dose for 3 periods. Collected at the following: pre-dose, and 10 min, 20 min, 30 min, 45 min, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, , 8, 12, 16 and 24h post-dose. ] [ Designated as safety issue: No ]
    Area under the plasma concentration-time curve [AUC(0 last)], Area under the plasma concentration-time curve [AUC(0-infinity)], Maximum observed plasma concentration (Cmax), Time to maximum observed plasma concentration (tmax), Plasma elimination half-life (t1/2), Area under the plasma concentration-time curve for the metabolite [AUCm(0-last)]/ Area under the plasma concentration-time curve for the parent [AUCp(0-last)], and AUCm(0-infinity)/AUCp(0-infinity) ratios.

  • Parts A and B: plasma glucose concentrations in healthy subjects [ Time Frame: Part A: up to 24 hours post dose for five periods. Part B: For 24 hours post dose for 3 periods. ] [ Designated as safety issue: No ]
  • Parts A and B: Urine chemistry lab measurements [ Time Frame: measurements will be obtained pre-dose, and over the following intervals: 0-2, 2-4, 4-6, 6-8, 8-12, and 12-24h during the dosing period. ] [ Designated as safety issue: No ]
    Urine samples for creatinine, glucose, and electrolytes (Na, K, Cl) measurements will be obtained.

  • Part B: Plasma glucose and insulin concentrations concentrations in subjects with type 2 diabetes mellitus following a 50g oral glucose challenge. [ Time Frame: On day -2 predose and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 10, 12 and 24h. ] [ Designated as safety issue: No ]
  • Safety and Tolerability as assessed by numbers of adverse events [ Time Frame: Part A: Approximately 58 days and Part B: Approximately 38 days. ] [ Designated as safety issue: No ]
    number of adverse events collected during study

  • Safety and Tolerability as assessed by change from baseline in vital sign measurements [ Time Frame: Part A: Approximately 58 days and Part B: Approximately 38 days. ] [ Designated as safety issue: No ]
    Blood pressure and heart rate.

  • urine glucose concentrations in subjects with type 2 diabetes mellitus following a 50g oral glucose challenge. [ Time Frame: On day -2 predose and at 0.5, 1, 1.5, 2, 4, 4.5, 5, 6, 8, 10, 12 and 24h. ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: September 2004
Study Completion Date: January 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part A Treatment 1
GSK189075A 20mg
Drug: GSK189075A
20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Other Name: GSK189075A
Experimental: Part A Treatment 2
GSK189075A 50mg
Drug: GSK189075A
20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Other Name: GSK189075A
Experimental: Part A Treatment 3
GSK189075A 150mg
Drug: GSK189075A
20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Other Name: GSK189075A
Experimental: Part A Treatment 4
GSK189075A 500mg
Drug: GSK189075A
20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Other Name: GSK189075A
Experimental: Part A Treatment 5
GSK189075A 1000mg
Drug: GSK189075A
20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Other Name: GSK189075A
Placebo Comparator: Placebo
Placebo
Other: Placebo
Placebo
Experimental: Part B Low dose
low dose chosen from Part A
Drug: GSK189075A
20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Other Name: GSK189075A
Experimental: Part B High Dose
high dose chosen from Part A
Drug: GSK189075A
20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Other Name: GSK189075A

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women must be of non-childbearing potential. Non-childbearing potential is defined as: Post-menopausal females defined as being amenorrhoeic for greater than one year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. However, if indicated, this should be confirmed by estradiol and FSH levels consistent with menopause (according to local laboratory ranges) Pre-menopausal females with a documented (medical report verification) hysterectomy or tubal ligation.
  • A negative pre-study urine drug screen. A minimum list of drugs that will be screened includes amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • Negative results for hepatitis C antibodies, hepatitis B surface antigen and HIV at screening, or have documented negative test results within the last 6 months.
  • Signed and dated written informed consent prior to admission to the study.
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
  • Subjects with the following clinical laboratory values: ALT and AST < 2 times the upper limit of normal at screening and prior to the first dose; fasting triglycerides < 400mg/dL at screening and prior to first dose; bilirubin < 1.5 times the upper limit of normal at screening and prior to the first dose (total; subjects above this limit may only be included if direct bilirubin is within normal limits).

Other values must be within the normal range or not clinically significant at screening and check-in. Abnormal values, deemed clinically significant by the principal investigator, must be cleared by the medical monitor at GSK.

  • Additional inclusion criteria for subjects in Part A: A subject will be eligible for inclusion in Part A of this study only if all of the following criteria apply: Healthy adult subjects aged 18 to 55 years inclusive, male and female subjects of non-childbearing potential.
  • Body weight greater than or equal to 50kg for men and greater than or equal to 45kg for women and BMI within the range 19.0 to 30.0kg/m2 inclusive.
  • Healthy as judged by responsible physician. No clinically significant abnormality identified on the medical or laboratory evaluation, including 12-lead ECG. A subject with a clinically significant abnormality, or laboratory parameters outside the reference range for this age group may be included only if the Investigator and Sponsor's Medical Monitor considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
  • Part B: A subject will be eligible for inclusion in Part B of this study only if all of the following criteria are met: Subjects with documented type 2 diabetes mellitus diagnosis (diagnosed not less than 6 months; HbA1c less than or equal to 10 % and FPG < 280 mg/dL at screening) who are either controlled by diet alone or monotherapy for a minimum of 3 months with either oral sulfonylureas, rosiglitazone, metformin, or acarbose. They must be willing/able to discontinue these medications during each dosing occasion for up to 72 hours (from check-in into the research unit until released after the last study assessment for each dosing period).
  • Adult men and women between 30 - 60 years inclusive. Women must be of non-childbearing potential.
  • BMI within the range 22 35kg/m2 inclusive.
  • Subjects taking stable regimens of medications commonly used as prevention in diabetics (aspirin, ACE inhibitors, and statins) will be allowed if their dose regimen(s) remain constant throughout the study period. Concurrent usage of prescribed medications other than the medications listed above may be allowed to continue only with Sponsor's consent.
  • No significant concomitant health problems other than type 2 diabetes mellitus and otherwise healthy as judged by a responsible physician.
  • Systolic/Diastolic blood pressure: greater than or equal to 80/60 mmHg and less than or equal to 150/95 mmHg at screening.

Exclusion Criteria:

  • History or presence of allergy to the study drug or drugs of this class or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History or presence of gastrointestinal, hepatic or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs. Any acute gastrointestinal illness within 2 weeks prior to dosing.
  • Use of diuretics, systemic corticosteroids, or any other medication that may result in electrolyte depletion, within 3 weeks of any scheduled dose.
  • Blood electrolyte (K, Na, Cl, Mg or Ca or bicarbonate) values outside of the reference range at screening and admission. No deviation will be permitted unless there has been discussion on an individual basis between sponsor and investigator for the following parameters: sodium, potassium, chloride, bicarbonate, calcium and magnesium.
  • If participation in the study will result in the subject having donated more than 1,500mL blood (males) or 1,000mL (females) in the previous 12 months and 6. where participation in study would result in donation of blood in excess of 550mL within a 56-day period.
  • As a result of the medical interview, physical examination for screening investigations, the Physician Responsible considers the volunteer unfit for the study.
  • They have suffered a urinary tract or bladder infection within 4 weeks of the start of the study.
  • Abuse of alcohol
  • Significant renal disease
  • Any clinically significant abnormality identified on the medical or laboratory evaluation, including 12-lead ECG and 24 h Holter monitoring. A subject with a clinically significant abnormality or laboratory parameters outside the reference range for this age group may be included only if the Investigator and Sponsor's Medical Monitor consider that the finding will not introduce additional risk factors and will not interfere with the study procedures
  • Participation in a study trial with any drug of new chemical entity within 90 days prior to the start of the study.
  • Male subject unwilling to abstain from, or use a condom during sexual intercourse with a pregnant or lactating female; or male subject unwilling to use a condom plus another form of contraception (e.g., spermicide, IUD, birth control pills taken by female partner, diaphragm with spermicide) during sexual intercourse with a female who could become pregnant. Any male subject unwilling to adhere to the above contraceptive criteria from administration of study medication until completion of follow-up procedures.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication and until released after the last study assessment after the last dosing period, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.
  • Part A: A subject will not be eligible for inclusion in Part A of this study if the following applies: Past or present disease, which as judged by the Investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease and endocrine disease.
  • Part B: A subject will not be eligible for inclusion in Part A of this study if any of the following criteria apply: Currently requiring insulin therapy, or has been on insulin therapy for the previous 3 months prior to the screening examination.
  • Medically unable or unwilling to discontinue their oral antidiabetic medications for up to 72 hours (from check-in into the research unit until released after the last study assessment for each dosing period).
  • Past or present disease (other than type 2 diabetes mellitus) as judged by the Investigator, which may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease and endocrine disease.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01571661

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01571661     History of Changes
Other Study ID Numbers: KG219017
Study First Received: March 15, 2012
Last Updated: April 3, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
KGT-1142
safety
pharmacokinetics
single-dose escalation
tolerability

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on April 15, 2014